. Ongoing treatment in comparison to the optimal pro-active strategy. Left panels: Dynamics of a constant treatment a 1 in relation to the optimal pro-active strategy. Right panels: Dynamics of a constant treatment a 2 in relation to the optimal pro-active strategy. In A & C solid blue lines represent the probability ratio of states L for ongoing treatment with a 1 or a 2 (strategy S 1 ) in relation to the optimal pro-active strategy (strategy S 2 ) i.e., (P (L|S 1 )/(P (L|S 2 ))). Magenta-and red dashed lines show the ratios for the sets M and H. In B & D, the solid black lines represent the ratio of death probabilities. The thin black horizontal lines represents the line of unity in all figures.
The model predicted HIV-dynamics, if no treatment switches were applied, relative to the dynamics under the optimal pro-active strategy are shown in Fig. S1A -D. Fig. S1A&C show the dynamics for the sets of states L, M and H. The set L denotes the set of states for which condition n C (M ) ≤ ℓ for all possible virus mutants M holds (i.e. undetectable total virus load), H refers to all states for which for at least one viral strain M , n C (M ) > m (high virus loads). The remaining viral states belong to M. Fig. S1B&D show the relative death probabilities for a constant treatment in relation to an optimal pro-active strategy. Figure S1A shows that the relative probability of set H (red dashed line; high viral loads) is higher if treatment with a 1 is maintained in comparison to the optimal pro-active strategy. After roughly 200 day, the probability of set H becomes ≈2.7 times the probability of set H in the pro-active strategy . Application of a 1 without treatment change also results in an increased death probability ( Figure S1B ) with a peak after about 1000 days. As a consequence of patient death, the relative probability of being in set H declines over time in Fig. S1A .
The comparison between ongoing treatment with a 2 and the optimal pro-active strategy is depicted in Figure S1C -D. For the first few weeks, the probability of set L is higher with a 2 and the death probability is lower than with the optimal pro-active strategy. However, the performance of the ongoing treatment with a 2 deteriorates and in the long term the optimal pro-active strategy outperforms ongoing treatment with a 2 . After roughly 200 days, the death rate is higher and probability of state L is lower for ongoing treatment with a 2 than with the optimal pro-active strategy. Therefore, the ongoing treatment with a 2 may be effective in the short term, but in the long term the emergence of drug resistant strains R2 may undermine its short-term efficacy. The optimal pro-active strategy delays the emergence of strains resistant to treatment a 2 and remains more effective in a long run.
